Key result
Semaglutide cuts MACE risk ~29% while tirzepatide shows no significant benefit.
Why the study?
Do semaglutide and tirzepatide reduce major adverse cardiovascular events in adults with type 2 diabetes mellitus, overweight or obesity?
Population
59,352 adults with type 2 diabetes mellitus (T2DM), overweight or obesity from 47 RCTs
Comparison
Semaglutide and tirzepatide vs Control
Design
Meta-analysis
Authors
Loading...
Semaglutide may lower MACE risk in T2DM or obesity; confirms benefit while leaving tirzepatide evidence inconclusive.
Meta-Analysis (n=59,352)
Yes
Do semaglutide and tirzepatide reduce major adverse cardiovascular events in adults with type 2 diabetes mellitus, overweight or obesity?
Relative Risk: 0.71 (95% CI 0.6–0.84)
p-value: p=<0.001
Semaglutide demonstrates a consistent reduction in major adverse cardiovascular events in adults with T2DM or obesity, whereas evidence for tirzepatide remains limited and uncertain.
Xiao-yu et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus, overweight, or obesity (n=59,352). Semaglutide and Tirzepatide vs. Placebo or active comparators was evaluated on Major adverse cardiovascular events (MACE) (RR 0.71, 95% CI 0.60-0.84, p=<0.001). Semaglutide significantly reduced the risk of major adverse cardiovascular events (RR 0.71), whereas the reduction with tirzepatide did not reach statistical significance (RR 0.79).
Synapse has enriched one closely related paper. Consider it for comparative context: